Related Experiment Videos
Inhibition of platelet function by uremic middle molecules
Nephron
|January 1, 1985
Summary
Uremic bleeding involves platelet dysfunction. Middle molecular weight substances in uremic serum inconsistently inhibit platelet aggregation, suggesting a complex cause for bleeding disorders in kidney disease.
Area of Science:
- Nephrology
- Hematology
- Biochemistry
Background:
- Uremic bleeding is a common complication in patients with kidney failure.
- The precise platelet defect causing uremic bleeding remains incompletely understood.
Purpose of the Study:
- To investigate the role of serum middle molecules in platelet dysfunction in uremic patients.
- To identify specific serum fractions that inhibit platelet aggregation.
Main Methods:
- Serum fractionation using Sephadex G-15 chromatography.
- Assessment of platelet aggregation using adenosine diphosphate, ristocetin, and collagen.
Main Results:
- Inhibition of platelet aggregation was observed in several middle molecular weight serum fractions.
- The observed inhibition was inconsistent among patients and did not correlate with the severity of uremia.
Conclusions:
- Serum middle molecules may contribute to platelet dysfunction in uremia.
- The inhibitory effect of these molecules is not consistently linked to the degree of kidney disease, indicating a complex etiology for uremic bleeding.